Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives

Pharmacology and Therapeutics

Volumn 138, Issue 2, 2013, Pages 294-309

  Tan, Seng Lai ^a   Liao, Cheng ^a   Lucas, Matthew C ^b   Stevenson, Christopher ^a   Demartino, Julie A ^a  

^a Inflammation Discovery   (United States)

^b Discovery Chemistry   (United States)

Author keywords

Autoimmunity; Hematologic cancers; Immunoreceptors; Inflammation; Kinase inhibitors

Indexed keywords

BARICITINIB; BRUTON TYROSINE KINASE; FC RECEPTOR; FOSTAMATINIB; GLYCOPROTEIN VI; IBRUTINIB; IDELALISIB; JANUS KINASE 3 INHIBITOR; LX 3305; OSTEOCLAST DIFFERENTIATION FACTOR; PATTERN RECOGNITION RECEPTOR; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PRT 062607; R 343; UNCLASSIFIED DRUG; VX 509;

ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DOWNSTREAM PROCESSING; DRUG TARGETING; ENZYME ACTIVITY; HEMATOLOGIC DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTOMA; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84875224608     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.02.001     Document Type: Review

References (169)

1. F. Abtahian, N. Bezman, R. Clemens, E. Sebzda, L. Cheng, and S.J. Shattil Evidence for the requirement of ITAM domains but not SLP-76/Gads interaction for integrin signaling in hematopoietic cells Mol Cell Biol 26 2006 6936 6949
2. F. Abtahian, A. Guerriero, E. Sebzda, M.M. Lu, R. Zhou, and A. Mocsai Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk Science 299 2003 247 251
3. I.L. Ahren, E. Eriksson, A. Egesten, and K. Riesbeck Nontypeable Haemophilus influenzae activates human eosinophils through beta-glucan receptors Am J Respir Cell Mol Biol 29 2003 598 605
4. A.H. Andreotti, P.L. Schwartzberg, R.E. Joseph, and L.J. Berg T-cell signaling regulated by the Tec family kinase, Itk Cold Spring Harb Perspect Biol 2 7 2010 a002287-a002287. http://dx.doi.org/10.1101/cshperspect.a002287 (Electronic publication ahead of print 2010 Jun 2 Review)
5. M. Asagiri, and H. Takayanagi The molecular understanding of osteoclast differentiation Bone 40 2007 251 264
6. F.R. Bahjat, P.R. Pine, A. Reitsma, G. Cassafer, M. Baluom, and S. Grillo An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Arthritis Rheum 58 2008 1433 1444
7. N.A. Barrett, A. Maekawa, O.M. Rahman, K.F. Austen, and Y. Kanaoka Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells J Immunol 182 2009 1119 1128
8. N.A. Barrett, O.M. Rahman, J.M. Fernandez, M.W. Parsons, W. Xing, and K.F. Austen Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes J Exp Med 208 2011 593 604
9. C.C. Bertozzi, P.R. Hess, and M.L. Kahn Platelets: covert regulators of lymphatic development Arterioscler Thromb Vasc Biol 30 2010 2368 2371
10. C.C. Bertozzi, A.A. Schmaier, P. Mericko, P.R. Hess, Z. Zou, and M. Chen Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling Blood 116 2010 661 670
11. E. Boilard, P.A. Nigrovic, K. Larabee, G.F. Watts, J.S. Coblyn, and M.E. Weinblatt Platelets amplify inflammation in arthritis via collagen-dependent microparticle production Science 327 2010 580 583
12. B. Boylan, C. Gao, V. Rathore, J.C. Gill, D.K. Newman, and P.J. Newman Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets Blood 112 2008 2780 2786
13. S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, and M. Baluom R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation J Pharmacol Exp Ther 319 2006 998 1008
14. V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, and D.S. Weiss Neutrophil extracellular traps kill bacteria Science 303 2004 1532 1535
15. J.R. Brown, J.P. Sharman, W.A. Harb, K.R. Kelly, M.T. Schreeder, and J.W. Sweetenham Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL) Presented at: 48th Annual Meeting of the American Society of Clinical Oncology; June 2012; Chicago, IL 2012 (Abstract 8032)
16. C. Brunner, B. Müller, and T. Wirth Bruton's Tyrosine Kinase is involved in innate and adaptive immunity Histol Histopathol 20 3 2005 945 955
17. J.J. Buggy, and L. Elias Bruton tyrosine kinase (BTK) and its role in B-cell malignancy Int Rev Immunol 31 2012 119 132
18. R. Buhl, G. Hanf, M. Soler, G. Bensch, J. Wolfe, and F. Everhard The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Eur Respir J 20 2002 1088 1094
19. R. Buhl, M. Soler, J. Matz, R. Townley, J. O'Brien, and O. Noga Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Eur Respir J 20 2002 73 78
20. J.B. Bussel, and K. Hanna Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura Am J Hematol 82 2007 192 198
21. J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, L. Kovaleva, and B. Meddeb Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura N Engl J Med 357 2007 2237 2247
22. B.Y. Chang, M.M. Huang, M. Francesco, J. Chen, J. Sokolove, and P. Magadala The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Arthritis Res Ther 13 2011 R115
23. A.K. Chauhan, and T.L. Moore Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells Clin Exp Immunol 167 2012 235 245
24. A.M. Cheng, B. Rowley, W. Pao, A. Hayday, J.B. Bolen, and T. Pawson Syk tyrosine kinase required for mouse viability and B-cell development Nature 378 1995 303 306
25. G. Coffey, F. DeGuzman, M. Inagaki, Y. Pak, S.M. Delaney, and D. Ives Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J Pharmacol Exp Ther 340 2012 350 359
26. M. Corr, and B. Crain The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis J Immunol 169 2002 6604 6609
27. S.W. Cowan-Jacob, H. Mobitz, and D. Fabbro Structural biology contributions to tyrosine kinase drug discovery Curr Opin Cell Biol 21 2009 280 287
28. J.C. Crispin, V.C. Kyttaris, C. Terhorst, and G.C. Tsokos T cells as therapeutic targets in SLE Nat Rev Rheumatol 6 2010 317 325
29. L. Danks, S. Workman, D. Webster, and N.J. Horwood Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts J Bone Miner Res 26 2011 182 192
30. M.F. de Rooij, A. Kuil, C.R. Geest, E. Eldering, B.Y. Chang, and J.J. Buggy The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Blood 119 2012 2590 2594
31. G.M. Deng, L. Liu, F.R. Bahjat, P.R. Pine, and G.C. Tsokos Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice Arthritis Rheum 62 2010 2086 2092
32. J.A. Di Paolo, T. Huang, M. Balazs, J. Barbosa, K.H. Barck, and B.J. Bravo Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis Nat Chem Biol 7 2011 41 50
33. C. Dierks, F. Adrian, P. Fisch, H. Ma, H. Maurer, and D. Herchenbach The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease Cancer Res 70 2010 6193 6204
34. D.G. Efremov, and L. Laurenti The Syk kinase as a therapeutic target in leukemia and lymphoma Expert Opin Investig Drugs 20 2011 623 636
35. E.R. Elliott, J.A. Van Ziffle, P. Scapini, B.M. Sullivan, R.M. Locksley, and C.A. Lowell Deletion of Syk in neutrophils prevents immune complex arthritis J Immunol 187 2011 4319 4330
36. E.J. Enyedy, M.P. Nambiar, S.N. Liossis, G. Dennis, G.M. Kammer, and G.C. Tsokos Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus Arthritis Rheum 44 2001 1114 1121
37. T. Evans, C. Aslanian, P. Mazdiyasni, S. Tesar, S. Nacht, and L. Witowski Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies 53rd ASH Meeting and Exposition 2011 (San Diego, CA)
38. E. Evans, R. Tester, S. Aslanian, P. Chaturvedi, R. Karp, and M. Labenski Translational medicine of a selective inhibitor of Btk in rheumatic diseases: pharmacology and early clinical development American College of Rheumatology (ACR) 2011 Vol. 63 2011 1 (Chicago, IL)
39. J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
40. A.L. Feldman, D.X. Sun, M.E. Law, A.J. Novak, A.D. Attygalle, and E.C. Thorland Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas Leukemia 22 2008 1139 1143
41. K. Fiedler, A. Sindrilaru, G. Terszowski, E. Kokai, T.B. Feyerabend, and L. Bullinger Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia Blood 117 2011 1329 1339
42. R. Fleischmann Novel small-molecular therapeutics for rheumatoid arthritis Curr Opin Rheumatol 24 2012 335 341
43. J.W. Friedberg, J. Sharman, J. Sweetenham, P.B. Johnston, J.M. Vose, and A. Lacasce Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2010 2578 2585
44. H. Fukuyama, F. Nimmerjahn, and J.V. Ravetch The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells Nat Immunol 6 2005 99 106
45. G.S. Garcia-Romo, S. Caielli, B. Vega, J. Connolly, F. Allantaz, and Z. Xu Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus Sci Transl Med 3 2011 73ra20
46. S. Gaubert, A. Viana da Costa, C.A. Maurage, E.C. Lima, J. Fontaine, and S. Lafitte X-linked immunodeficiency affects the outcome of Schistosoma mansoni infection in the murine model Parasite Immunol 21 1999 89 101
47. M.C. Genovese, A. Kavanaugh, M.E. Weinblatt, C. Peterfy, J. DiCarlo, and M.L. White An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents Arthritis Rheum 63 2011 337 345
48. A. Ghigo, F. Damilano, L. Braccini, and E. Hirsch PI3K inhibition in inflammation: toward tailored therapies for specific diseases Bioessays 32 2010 185 196
49. D. Ghosh, G.C. Tsokos, and V.C. Kyttaris c-Jun and Ets2 regulate the expression of spleen tyrosine kinase in T cells J Biol Chem 287 15 2012 11833 11841 10.1074/jbc.M111.333997 (Electronic publication ahead of print 2012 Feb 21)
50. E.A. Goldings Defective B cell tolerance induction in New Zealand black mice. I. Macrophage independence and comparison with other autoimmune strains J Immunol 131 1983 2630 2634
51. S.I. Gringhuis, T.M. Kaptein, B.A. Wevers, B. Theelen, M. van der Vlist, and T. Boekhout Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome Nat Immunol 13 2012 246 254
52. O. Gross, H. Poeck, M. Bscheider, C. Dostert, N. Hannesschlager, and S. Endres Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence Nature 459 2009 433 436
53. C.K. Hahn, J.E. Berchuck, K.N. Ross, R.M. Kakoza, K. Clauser, and A.C. Schinzel Proteomic and genetic approaches identify Syk as an AML target Cancer Cell 16 2009 281 294
54. K.E. Halcomb, S. Musuka, T. Gutierrez, H.L. Wright, and A.B. Satterthwaite Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells Mol Immunol 46 2008 233 241
55. J. Hall, A. Aulabaugh, F. Rajamohan, S. Liu, N. Kaila, and Z.K. Wan Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase J Biol Chem 287 2012 7717 7727
56. H. Hammad, M. Chieppa, F. Perros, M.A. Willart, R.N. Germain, and B.N. Lambrecht House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells Nat Med 15 2009 410 416
57. S.J. Harris, J.G. Foster, and S.G. Ward PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies Curr Opin Investig Drugs 10 2009 1151 1162
58. C. Harrison Trial watch: BTK inhibitor shows positive results in B cell malignancies Nat Rev Drug Discov 11 2012 96
59. S.E. Herman, A.L. Gordon, E. Hertlein, A. Ramanunni, X. Zhang, and S. Jaglowski Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 117 2011 6287 6296
60. A. Hoerauf, W. Solbach, M. Lohoff, and M. Rollinghoff The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice Int Immunol 6 1994 1117 1124
61. S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lotvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
62. F. Honda, H. Kano, H. Kanegane, S. Nonoyama, E.S. Kim, and S.K. Lee The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils Nat Immunol 13 2012 369 378
63. L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, and B. Chang The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 107 2010 13075 13080
64. J. Hsu, Y. Gu, S.L. Tan, S. Narula, J.A. DeMartino, and C. Liao Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints Immunol Lett 2012 10.1016/j.imlet.2012.12.007
65. C.E. Hughes, A.Y. Pollitt, J. Mori, J.A. Eble, M.G. Tomlinson, and J.H. Hartwig CLEC-2 activates Syk through dimerization Blood 115 2010 2947 2955
66. J. Hutcheson, K. Vanarsa, A. Bashmakov, S. Grewal, D. Sajitharan, and B.Y. Chang Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus Arthritis Res Ther 14 6 2012, Nov 8 R243 (Epub ahead of print)
67. Z. Jakus, E. Simon, B. Balazs, and A. Mocsai Genetic deficiency of Syk protects mice from autoantibody-induced arthritis Arthritis Rheum 62 2010 1899 1910
68. L. Jansson, and R. Holmdahl Genes on the X chromosome affect development of collagen-induced arthritis in mice Clin Exp Immunol 94 1993 459 465
69. H. Ji, K. Ohmura, U. Mahmood, D.M. Lee, F.M. Hofhuis, and S.A. Boackle Arthritis critically dependent on innate immune system players Immunity 16 2002 157 168
70. S.L. Johnston, P.K. Pattemore, G. Sanderson, S. Smith, F. Lampe, and L. Josephs Community study of role of viral infections in exacerbations of asthma in 9-11 year old children BMJ 310 1995 1225 1229
71. T. Kagari, D. Tanaka, H. Doi, and T. Shimozato Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis J Immunol 170 2003 4318 4324
72. T. Kanie, A. Abe, T. Matsuda, Y. Kuno, M. Towatari, and T. Yamamoto TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways Leukemia 18 2004 548 555
73. Y. Kawakami, N. Inagaki, S. Salek-Ardakani, J. Kitaura, H. Tanaka, and K. Nagao Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3 Proc Natl Acad Sci U S A 103 2006 153 158
74. Y. Kawakami, J. Kitaura, S.E. Hartman, C.A. Lowell, R.P. Siraganian, and T. Kawakami Regulation of protein kinase CbetaI by two protein-tyrosine kinases, Btk and Syk Proc Natl Acad Sci U S A 97 2000 7423 7428
75. F. Kiefer, J. Brumell, N. Al-Alawi, S. Latour, A. Cheng, and A. Veillette The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils Mol Cell Biol 18 1998 4209 4220
76. T.M. Kim, S.A. Ha, H.K. Kim, J. Yoo, S. Kim, and S.H. Yim Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib Blood Cancer J 1 2011 e32
77. E.A. Knijff-Dutmer, J. Koerts, R. Nieuwland, E.M. Kalsbeek-Batenburg, and M.A. van de Laar Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis Arthritis Rheum 46 2002 1498 1503
78. T. Koga, M. Inui, K. Inoue, S. Kim, A. Suematsu, and E. Kobayashi Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis Nature 428 2004 758 763
79. R. Kozaki, T. Yoshizawa, T. Yasuhiro, J.F. Mirjolet, J. Birkett, and M. Narita Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies Cancer Research 72 8 2012 10.1158/1538-7445.AM2012-857 (Supplement 1, Link: http://cancerres.aacrjournals. org/cgi/content/meeting-abstract/72/8-MeetingAbstracts/857)
80. S. Krishnan, Y.T. Juang, B. Chowdhury, A. Magilavy, C.U. Fisher, and H. Nguyen Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells J Immunol 181 2008 8145 8152
81. S. Krishnan, V.G. Warke, M.P. Nambiar, G.C. Tsokos, and D.L. Farber The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells J Immunol 170 2003 4189 4195
82. Y. Kuno, A. Abe, N. Emi, M. Iida, T. Yokozawa, and M. Towatari Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12) Blood 97 2001 1050 1055
83. R. Lande, D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, and J. Gregorio Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus Sci Transl Med 3 2011 73ra19
84. P. Lebrun, C.L. Sidman, and H.L. Spiegelberg IgE formation and Fc receptor-positive lymphocytes in normal, immuno-deficient, and auto-immune mice infected with Nippostrongylus brasiliensis J Immunol 141 1988 249 257
85. S.H. Lee, T. Kim, D. Jeong, N. Kim, and Y. Choi The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation J Biol Chem 283 2008 11526 11534
86. K.G. Lee, S. Xu, Z.H. Kang, J. Huo, M. Huang, and D. Liu Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response Proc Natl Acad Sci U S A 109 2012 5791 5796
87. S. LeibundGut-Landmann, O. Gross, M.J. Robinson, F. Osorio, E.C. Slack, and S.V. Tsoni Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 Nat Immunol 8 2007 630 638
88. A.J. Leishman, G.P. Sims, M. Sleeman, and M. Braddock Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity Expert Opin Investig Drugs 20 2011 23 39
89. C. Liao, and D.R. Littman Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk Immunity 3 1995 757 769
90. H. Liao, Gu, and DeMartino Platelets amplify inflammation through GPVI and CLEC-2 receptors leading to BTK-dependent generation of microparticles K. Symposia, Rheumatoid arthritis: molecular and clinical insights 2012 Keystone Symposia Santa Fe, NM
91. J. Liddle, F.L. Atkinson, M.D. Barker, P.S. Carter, N.R. Curtis, and R.P. Davis Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg Med Chem Lett 21 2011 6188 6194
92. X. Liu, Z. Zhan, D. Li, L. Xu, F. Ma, and P. Zhang Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk Nat Immunol 12 2011 416 424
93. Y. Lou, T.D. Owens, A. Kuglstatter, R.K. Kondru, and D.M. Goldstein Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies J Med Chem 55 2012 4539 4550
94. S.K. Lundy, A.A. Berlin, T.F. Martens, and N.W. Lukacs Deficiency of regulatory B cells increases allergic airway inflammation Inflamm Res 54 2005 514 521
95. D. MacGlashan Jr., L.A. Honigberg, A. Smith, J. Buggy, and J.T. Schroeder Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor Int Immunopharmacol 11 2011 475 479
96. A. Mangla, A. Khare, V. Vineeth, N.N. Panday, A. Mukhopadhyay, and B. Ravindran Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses Blood 104 2004 1191 1197
97. E.S. Masuda, and J. Schmitz Syk inhibitors as treatment for allergic rhinitis Pulm Pharmacol Ther 21 2008 461 467
98. S. Matsubara, T. Koya, K. Takeda, A. Joetham, N. Miyahara, and P. Pine Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation Am J Respir Cell Mol Biol 34 2006 426 433
99. S. Matsubara, G. Li, K. Takeda, J.E. Loader, P. Pine, and E.S. Masuda Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness Am J Respir Crit Care Med 173 2006 56 63
100. E.O. Meltzer, R.B. Berkowitz, and E.B. Grossbard An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment J Allergy Clin Immunol 115 2005 791 796
101. P. Minoprio, A. Coutinho, S. Spinella, and M. Hontebeyrie-Joskowicz Xid immunodeficiency imparts increased parasite clearance and resistance to pathology in experimental Chagas' disease Int Immunol 3 1991 427 433
102. A. Mocsai, C.L. Abram, Z. Jakus, Y. Hu, L.L. Lanier, and C.A. Lowell Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs Nat Immunol 7 2006 1326 1333
103. A. Mocsai, M.B. Humphrey, J.A. Van Ziffle, Y. Hu, A. Burghardt, and S.C. Spusta The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase Proc Natl Acad Sci U S A 101 2004 6158 6163
104. A. Mocsai, J. Ruland, and V.L. Tybulewicz The SYK tyrosine kinase: a crucial player in diverse biological functions Nat Rev Immunol 10 2010 387 402
105. A. Mocsai, M. Zhou, F. Meng, V.L. Tybulewicz, and C.A. Lowell Syk is required for integrin signaling in neutrophils Immunity 16 2002 547 558
106. A.F. Moretto, C. Dehnhardt, N. Kaila, N. Papaioannou, and A. Thorarensen The 2010 patent landscape for spleen tyrosine kinase inhibitors Recent Pat Inflamm Allergy Drug Discov 6 2012 97 120
107. M. Moroi, and S.M. Jung Platelet glycoprotein VI: its structure and function Thromb Res 114 2004 221 233
108. H. Mueller, A. Stadtmann, H. Van Aken, E. Hirsch, D. Wang, and K. Ley Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways Blood 115 2010 3118 3127
109. M.P. Nambiar, C.U. Fisher, A. Kumar, C.G. Tsokos, V.G. Warke, and G.C. Tsokos Forced expression of the Fc receptor gamma-chain renders human T cells hyperresponsive to TCR/CD3 stimulation J Immunol 170 2003 2871 2876
110. A.T. Nathan, E.A. Peterson, J. Chakir, and M. Wills-Karp Innate immune responses of airway epithelium to house dust mite are mediated through beta-glucan-dependent pathways J Allergy Clin Immunol 123 2009 612 618
111. F. Nimmerjahn, and J.V. Ravetch Fcgamma receptors as regulators of immune responses Nat Rev Immunol 8 2008 34 47
112. A. Obergfell, K. Eto, A. Mocsai, C. Buensuceso, S.L. Moores, and J.S. Brugge Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton J Cell Biol 157 2002 265 275
113. T.L. O'Keefe, G.T. Williams, F.D. Batista, and M.S. Neuberger Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies J Exp Med 189 1999 1307 1313
114. E.H. Palacios, and A. Weiss Distinct roles for Syk and ZAP-70 during early thymocyte development J Exp Med 204 2007 1703 1715
115. O.N. Pamuk, and G.C. Tsokos Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases Arthritis Res Ther 12 2010 222
116. K. Pechloff, J. Holch, U. Ferch, M. Schweneker, K. Brunner, and M. Kremer The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma J Exp Med 207 2010 1031 1044
117. A. Podolanczuk, A.H. Lazarus, A.R. Crow, E. Grossbard, and J.B. Bussel Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk Blood 113 2009 3154 3160
118. A. Poole, J.M. Gibbins, M. Turner, M.J. van Vugt, J.G. van de Winkel, and T. Saito The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen EMBO J 16 1997 2333 2341
119. L.S. Quek, J. Bolen, and S.P. Watson A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen Curr Biol 8 1998 1137 1140
120. T. Rauen, C.M. Hedrich, Y.T. Juang, K. Tenbrock, and G.C. Tsokos cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus J Biol Chem 286 2011 43437 43446
121. D.J. Rawlings, D.C. Saffran, S. Tsukada, D.A. Largaespada, J.C. Grimaldi, and L. Cohen Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice Science 261 1993 358 361
122. Rigel Press release (2012, Aug. 7). (Website: http://www.prnewswire.com/ news-releases/rigel-announces-second-quarter-2012-financial-results-165250556. html).
123. P. Robak, and T. Robak A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia Curr Med Chem 19 31 2012 5294 5318
124. T. Robak, and E. Robak Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders Expert Opin Investig Drugs 21 2012 921 947
125. M.J. Robinson, F. Osorio, M. Rosas, R.P. Freitas, E. Schweighoffer, and O. Gross Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection J Exp Med 206 2009 2037 2051
126. M.A. Sanjuan, N. Rao, K.T. Lai, Y. Gu, S. Sun, and A. Fuchs CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion J Cell Biol 172 2006 1057 1068
127. A.B. Satterthwaite, C.A. Lowell, W.N. Khan, P. Sideras, F.W. Alt, and O.N. Witte Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways J Exp Med 188 1998 833 844
128. C. Sedlik, D. Orbach, P. Veron, E. Schweighoffer, F. Colucci, and R. Gamberale A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation J Immunol 170 2003 846 852
129. J. Sellam, V. Proulle, A. Jungel, M. Ittah, C. Miceli Richard, and J.E. Gottenberg Increased levels of circulating microparticles in primary Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity Arthritis Res Ther 11 2009 R156
130. J.W. Semple, J.E. Italiano Jr., and J. Freedman Platelets and the immune continuum Nat Rev Immunol 11 2011 264 274
131. M. Shinohara, T. Koga, K. Okamoto, S. Sakaguchi, K. Arai, and H. Yasuda Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals Cell 132 2008 794 806
132. M.T. Shio, S.C. Eisenbarth, M. Savaria, A.F. Vinet, M.J. Bellemare, and K.W. Harder Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases PLoS Pathog 5 2009 e1000559
133. A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, and N. Bardeesy A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival Cancer Cell 15 2009 489 500
134. A.D. Steinberg, D.M. Klinman, D.L. Kastner, M.F. Seldin, W.C. Gause, and C.L. Scribner Genetic and molecular genetic studies of murine and human lupus J Rheumatol Suppl 14 Suppl. 13 1987 166 176
135. A.D. Steinberg, H.R. Smith, C.A. Laskin, B.J. Steinberg, and J.S. Smolen Studies of immune abnormalities in systemic lupus erythematosus Am J Kidney Dis 2 1982 101 110
136. B. Streubel, U. Vinatzer, M. Willheim, M. Raderer, and A. Chott Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma Leukemia 20 2006 313 318
137. A. Sultan, W.C.Y., G.E. Duran, B. Franciso, J.S. Berek, and B.I. Sikic SYK inhibition results in increased sensitivity of OVCAR-3 cells to paclitaxel Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 3496 2010
138. K. Suzuki-Inoue, G.L. Fuller, A. Garcia, J.A. Eble, S. Pohlmann, and O. Inoue A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2 Blood 107 2006 542 549
139. K. Suzuki-Inoue, O. Inoue, and Y. Ozaki Novel platelet activation receptor CLEC-2: from discovery to prospects J Thromb Haemost 9 Suppl. 1 2011 44 55
140. Y.T. Tai, B.Y. Chang, S.Y. Kong, M. Fulciniti, G. Yang, and Y. Calle Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma Blood 120 9 2012 1877 1887 10.1182/blood-2011-12-396853
141. H. Takeshita, I. Taniuchi, J. Kato, and T. Watanabe Abrogation of autoimmune disease in Lyn-deficient mice by the mutation of the Btk gene Int Immunol 10 1998 435 444
142. P. Takhar, C.J. Corrigan, L. Smurthwaite, B.J. O'Connor, S.R. Durham, and T.H. Lee Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma J Allergy Clin Immunol 119 2007 213 218
143. K. Terato, K.A. Hasty, R.A. Reife, M.A. Cremer, A.H. Kang, and J.M. Stuart Induction of arthritis with monoclonal antibodies to collagen J Immunol 148 1992 2103 2108
144. J.D. Thomas, P. Sideras, C.I. Smith, I. Vorechovsky, V. Chapman, and W.E. Paul Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes Science 261 1993 355 358
145. S. Tsukada, D.C. Saffran, D.J. Rawlings, O. Parolini, R.C. Allen, and I. Klisak Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Cell 72 1993 279 290
146. M. Turner, P.J. Mee, P.S. Costello, O. Williams, A.A. Price, and L.P. Duddy Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk Nature 378 1995 298 302
147. F.M. Uckun, and S. Qazi Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity Expert Opin Ther Pat 20 2010 1457 1470
148. D.T. Umetsu, and R.H. Dekruyff Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma J Allergy Clin Immunol 125 2010 975 979
149. A.K. Vaishnaw, J. Gollob, C. Gamba-Vitalo, R. Hutabarat, D. Sah, and R. Meyers A status report on RNAi therapeutics Silence 1 2010 14
150. J.A. Van Ziffle, and C.A. Lowell Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection Blood 114 2009 4871 4882
151. D. Vetrie, I. Vorechovsky, P. Sideras, J. Holland, A. Davies, and F. Flinter The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases Nature 361 1993 226 233
152. B.O. Villoutreix, G. Laconde, D. Lagorce, P. Martineau, M.A. Miteva, and P. Dariavach Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening PLoS One 6 2011 e21117
153. M.J. Walter, J.D. Morton, N. Kajiwara, E. Agapov, and M.J. Holtzman Viral induction of a chronic asthma phenotype and genetic segregation from the acute response J Clin Invest 110 2002 165 175
154. S.P. Watson, J.M. Auger, O.J. McCarty, and A.C. Pearce GPVI and integrin alphaIIb beta3 signaling in platelets J Thromb Haemost 3 2005 1752 1762
155. M.E. Weinblatt, A. Kavanaugh, R. Burgos-Vargas, A.H. Dikranian, G. Medrano-Ramirez, and J.L. Morales-Torres Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial Arthritis Rheum 58 2008 3309 3318
156. M.E. Weinblatt, A. Kavanaugh, M.C. Genovese, T.K. Musser, E.B. Grossbard, and D.B. Magilavy An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis N Engl J Med 363 2010 1303 1312
157. -/- mice J Immunol 171 2003 1850 1858
158. M. Wills-Karp, A. Nathan, K. Page, and C.L. Karp New insights into innate immune mechanisms underlying allergenicity Mucosal Immunol 3 2010 104 110
159. D.R. Wilson, T.G. Merrett, E.M. Varga, L. Smurthwaite, H.J. Gould, and M. Kemp Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics Am J Respir Crit Care Med 165 2002 22 26
160. J.A. Woyach, A.J. Johnson, and J.C. Byrd The B-cell receptor signaling pathway as a therapeutic target in CLL Blood 120 6 2012 1175 1184
161. Q. Wu, R.J. Martin, S. Lafasto, B.J. Efaw, J.G. Rino, and R.J. Harbeck Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance Am J Respir Crit Care Med 177 2008 720 729
162. D. Xu, Y. Kim, J. Postelnek, M.D. Vu, D.Q. Hu, and C. Liao RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents J Pharmacol Exp Ther 341 2012 90 103
163. S. Yanagi, R. Inatome, T. Takano, and H. Yamamura Syk expression and novel function in a wide variety of tissues Biochem Biophys Res Commun 288 3 2001 495 498 (Review)
164. J. Zhang, C.A. Benavente, J. McEvoy, J. Flores-Otero, L. Ding, and X. Chen A novel retinoblastoma therapy from genomic and epigenetic analyses Nature 481 2012 329 334
165. J. Zikherman, M. Hermiston, D. Steiner, K. Hasegawa, A. Chan, and A. Weiss PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background J Immunol 182 2009 4093 4106
166. J. Zikherman, and A. Weiss Antigen receptor signaling in the rheumatic diseases Arthritis Res Ther 11 2009 202
167. W. Zou, H. Kitaura, J. Reeve, F. Long, V.L. Tybulewicz, and S.J. Shattil Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption J Cell Biol 176 2007 877 888
168. W. Zou, J.L. Reeve, Y. Liu, S.L. Teitelbaum, and F.P. Ross DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk Mol Cell 31 2008 422 431
169. M. Zouali, and G. Sarmay B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment Arthritis Rheum 50 2004 2730 2741